JP2020530831A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530831A5 JP2020530831A5 JP2019572817A JP2019572817A JP2020530831A5 JP 2020530831 A5 JP2020530831 A5 JP 2020530831A5 JP 2019572817 A JP2019572817 A JP 2019572817A JP 2019572817 A JP2019572817 A JP 2019572817A JP 2020530831 A5 JP2020530831 A5 JP 2020530831A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- hormone
- agent according
- crf
- receptor antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 27
- 229940124597 therapeutic agent Drugs 0.000 claims 27
- 208000005676 Adrenogenital syndrome Diseases 0.000 claims 12
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 12
- 239000005556 hormone Substances 0.000 claims 12
- 229940088597 hormone Drugs 0.000 claims 12
- 239000002464 receptor antagonist Substances 0.000 claims 10
- 229940044551 receptor antagonist Drugs 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims 5
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 5
- 101800000414 Corticotropin Proteins 0.000 claims 5
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims 5
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 5
- 229960000258 corticotropin Drugs 0.000 claims 5
- 239000003862 glucocorticoid Substances 0.000 claims 3
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000010419 fine particle Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 229960005471 androstenedione Drugs 0.000 claims 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023146415A JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2024179270A JP2025020148A (ja) | 2017-08-14 | 2024-10-11 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545406P | 2017-08-14 | 2017-08-14 | |
| US62/545,406 | 2017-08-14 | ||
| PCT/US2018/046760 WO2019036503A1 (en) | 2017-08-14 | 2018-08-14 | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146415A Division JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530831A JP2020530831A (ja) | 2020-10-29 |
| JP2020530831A5 true JP2020530831A5 (cg-RX-API-DMAC7.html) | 2021-09-24 |
| JP7398963B2 JP7398963B2 (ja) | 2023-12-15 |
Family
ID=65362494
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572817A Active JP7398963B2 (ja) | 2017-08-14 | 2018-08-14 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2023146415A Active JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2024179270A Pending JP2025020148A (ja) | 2017-08-14 | 2024-10-11 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146415A Active JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2024179270A Pending JP2025020148A (ja) | 2017-08-14 | 2024-10-11 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (9) | US20210361664A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3628005A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7398963B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250022913A (cg-RX-API-DMAC7.html) |
| CN (2) | CN118845788A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018317398A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020002967A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3064464A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202090450A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2019015320A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019036503A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6585625B2 (ja) | 2014-01-21 | 2019-10-02 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
| EP3628005A4 (en) | 2017-08-14 | 2021-01-20 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
| CN112423747A (zh) | 2018-04-27 | 2021-02-26 | 云杉生物科学公司 | 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法 |
| TW202446384A (zh) | 2018-12-07 | 2024-12-01 | 美商紐羅克里生物科學有限公司 | 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式 |
| AU2020318970A1 (en) | 2019-07-19 | 2022-03-03 | Spruce Biosciences, Inc. | Methods of treating congenital adrenal hyperplasia |
| CN114502162B (zh) | 2019-09-27 | 2025-03-28 | 纽罗克里生物科学有限公司 | Crf受体拮抗剂及使用方法 |
| CN118948857A (zh) * | 2020-08-12 | 2024-11-15 | 云杉生物科学公司 | 用于治疗多囊卵巢综合征的方法和组合物 |
| US20240024330A1 (en) * | 2020-08-26 | 2024-01-25 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| WO2025188842A1 (en) * | 2024-03-08 | 2025-09-12 | Spruce Biosciences, Inc. | Amorphous solid dispersion of tildacerfont formulations |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0173172B1 (ko) | 1992-12-17 | 1999-02-01 | 알렌 제이. 스피겔 | Crf 길항제로서의 피롤로피리미딘 |
| KR100421626B1 (ko) | 1996-02-07 | 2004-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | Crf수용체에대한길항제로서의피라졸로피리미딘 |
| DK0915880T3 (da) | 1996-07-24 | 2008-02-11 | Bristol Myers Squibb Pharma Co | Azolotriaziner og pyrimidiner |
| EA004403B1 (ru) | 1996-07-24 | 2004-04-29 | Дюпон Фармасьютикалз Компани | Производные пиразолотриазинов, фармацевтические композиции, содержащие их, способы лечения |
| JP3621706B2 (ja) | 1996-08-28 | 2005-02-16 | ファイザー・インク | 置換された６，５―ヘテロ―二環式誘導体 |
| IL137019A (en) | 1998-01-28 | 2010-11-30 | Du Pont Pharm Co | 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them |
| JP4228332B2 (ja) | 1998-01-28 | 2009-02-25 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | アゾロトリアジン類およびアゾロピリミジン類 |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| WO2000059908A2 (en) | 1999-04-06 | 2000-10-12 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| US6476038B1 (en) | 1999-09-30 | 2002-11-05 | Neurogen Corporation | Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| WO2001041761A2 (en) | 1999-12-08 | 2001-06-14 | Pharmacia Corporation | Valdecoxib compositions |
| ES2282401T3 (es) | 2001-03-13 | 2007-10-16 | Bristol-Myers Squibb Pharma Company | 4-(2-butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il) pirazolo - 1,5-a-1,3,5-triazina, sus enantiomeros y sales farmaceuticamente aceptables como ligandos del receptor del factor liberador de croticotropina. |
| WO2005020910A2 (en) | 2003-08-27 | 2005-03-10 | Pharmacia Corporation | Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries |
| PL1708790T3 (pl) | 2003-12-02 | 2010-10-29 | Pharmaneuroboost N V | Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych |
| EP1697374B1 (en) | 2003-12-22 | 2012-08-29 | SmithKline Beecham (Cork) Limited | Crf receptor antagonists and methods relating thereto |
| US20070129382A1 (en) | 2004-02-13 | 2007-06-07 | Dimitri Grigoriadis | Crf receptor antagonists, their preparations, their pharmaceutical composition, and their uses |
| RU2006129307A (ru) | 2004-02-13 | 2008-02-20 | Пфайзер Продактс Инк. (Us) | Терапевтические комбинации атипичных нейролептиков с антагонистами кортикотропин-рилизинг фактора |
| US20060078623A1 (en) * | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| CN101142217B (zh) | 2005-03-21 | 2010-12-08 | 伊莱利利公司 | 咪唑并哒嗪化合物 |
| CN101516835A (zh) | 2006-07-19 | 2009-08-26 | 俄亥俄州立大学研究基金会 | 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途 |
| ES2428543T3 (es) | 2006-09-20 | 2013-11-08 | Eli Lilly And Company | Compuestos de tiofenopirazolopirimidina |
| NZ575572A (en) * | 2006-09-20 | 2011-10-28 | Lilly Co Eli | Thiazole pyrazolopyrimidines as crf1 receptor antagonists |
| US8952207B2 (en) | 2007-09-11 | 2015-02-10 | The University Of Houston System | Copper-catalyzed C—H bond arylation |
| US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| DK2350079T3 (da) | 2008-10-02 | 2012-12-17 | Lilly Co Eli | Thiazolylpyrazolopyrimidinforbindelser som syntetiske mellemprodukter og dertil relaterede syntetiske fremgangsmåder |
| EP3486648B1 (en) * | 2008-12-24 | 2025-04-30 | Quest Diagnostics Investments Incorporated | Mass spectrometry assay for congenital adrenal hyperplasia |
| CA2822435C (en) * | 2009-12-31 | 2018-09-11 | Differential Drug Development Associates, Llc | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
| US9750568B2 (en) | 2012-03-08 | 2017-09-05 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
| JP2015516979A (ja) | 2012-04-23 | 2015-06-18 | ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒ Ｎｅｕｒｏｃｈｅｍｉｅ Ｇｍｂｈ | Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト |
| JP6585625B2 (ja) * | 2014-01-21 | 2019-10-02 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
| AU2016242867B2 (en) | 2015-03-31 | 2020-11-05 | May Health Us Inc. | Methods and systems for the manipulation of ovarian tissues |
| CN110997667A (zh) | 2017-08-14 | 2020-04-10 | 云杉生物科学公司 | 促肾上腺皮质激素释放因子受体拮抗剂 |
| EP3628005A4 (en) | 2017-08-14 | 2021-01-20 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
| CN112423747A (zh) | 2018-04-27 | 2021-02-26 | 云杉生物科学公司 | 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法 |
| TW202446384A (zh) | 2018-12-07 | 2024-12-01 | 美商紐羅克里生物科學有限公司 | 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式 |
| US20200255436A1 (en) | 2019-02-12 | 2020-08-13 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
| AU2020318970A1 (en) | 2019-07-19 | 2022-03-03 | Spruce Biosciences, Inc. | Methods of treating congenital adrenal hyperplasia |
| CN118948857A (zh) | 2020-08-12 | 2024-11-15 | 云杉生物科学公司 | 用于治疗多囊卵巢综合征的方法和组合物 |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| EP4402142A4 (en) | 2021-11-19 | 2025-07-23 | Spruce Biosciences Inc | CRYSTALLINE COMPOSITION OF TILDACERFONT AND ITS METHODS OF USE AND PREPARATION |
-
2018
- 2018-08-14 EP EP18846689.0A patent/EP3628005A4/en active Pending
- 2018-08-14 CA CA3064464A patent/CA3064464A1/en active Pending
- 2018-08-14 KR KR1020257004457A patent/KR20250022913A/ko active Pending
- 2018-08-14 JP JP2019572817A patent/JP7398963B2/ja active Active
- 2018-08-14 CN CN202410709847.0A patent/CN118845788A/zh active Pending
- 2018-08-14 US US16/639,541 patent/US20210361664A1/en not_active Abandoned
- 2018-08-14 AU AU2018317398A patent/AU2018317398A1/en not_active Abandoned
- 2018-08-14 KR KR1020207004095A patent/KR20200040761A/ko not_active Ceased
- 2018-08-14 CN CN201880038569.3A patent/CN110996943A/zh active Pending
- 2018-08-14 EA EA202090450A patent/EA202090450A1/ru unknown
- 2018-08-14 BR BR112020002967-0A patent/BR112020002967A2/pt not_active Application Discontinuation
- 2018-08-14 WO PCT/US2018/046760 patent/WO2019036503A1/en not_active Ceased
- 2018-08-14 MX MX2019015320A patent/MX2019015320A/es unknown
-
2019
- 2019-04-18 US US16/388,620 patent/US10849908B2/en active Active
- 2019-12-16 MX MX2023000501A patent/MX2023000501A/es unknown
-
2020
- 2020-10-05 US US17/063,592 patent/US11344557B2/en active Active
- 2020-10-22 US US17/078,054 patent/US11007201B2/en active Active
-
2021
- 2021-06-25 US US17/359,414 patent/US11311549B2/en active Active
- 2021-06-25 US US17/359,411 patent/US11351177B2/en active Active
-
2022
- 2022-01-27 US US17/586,228 patent/US20220143037A1/en not_active Abandoned
- 2022-12-09 US US18/078,649 patent/US20230321112A1/en active Pending
-
2023
- 2023-01-13 AU AU2023200189A patent/AU2023200189B2/en active Active
- 2023-04-26 US US18/307,718 patent/US12115166B2/en active Active
- 2023-09-08 JP JP2023146415A patent/JP7573080B2/ja active Active
-
2024
- 2024-10-11 JP JP2024179270A patent/JP2025020148A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530831A5 (cg-RX-API-DMAC7.html) | ||
| Auchus et al. | Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer | |
| JP2019509351A5 (cg-RX-API-DMAC7.html) | ||
| JP2016538270A5 (cg-RX-API-DMAC7.html) | ||
| JP2009215293A5 (cg-RX-API-DMAC7.html) | ||
| EP3923920A1 (en) | Ketamine for the treatment of postpartum symptoms and disorders | |
| JP2016185995A5 (cg-RX-API-DMAC7.html) | ||
| KR20200038951A (ko) | 코티코트로핀 방출 인자 수용체 길항제 | |
| Tseng et al. | Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs | |
| JP2019517511A5 (cg-RX-API-DMAC7.html) | ||
| JP2019525948A5 (cg-RX-API-DMAC7.html) | ||
| KR20200040761A (ko) | 코티코트로핀 방출 인자 수용체 길항제 | |
| JP2020516646A5 (cg-RX-API-DMAC7.html) | ||
| JP2017529388A5 (cg-RX-API-DMAC7.html) | ||
| JP2017533220A5 (cg-RX-API-DMAC7.html) | ||
| JP2017526697A5 (cg-RX-API-DMAC7.html) | ||
| US20140329782A1 (en) | Combined therapeutic agent | |
| JP2018503610A5 (cg-RX-API-DMAC7.html) | ||
| JP2024510260A (ja) | 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト | |
| Baughman et al. | Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents | |
| JP2020500864A5 (cg-RX-API-DMAC7.html) | ||
| KR20220164539A (ko) | SARS-CoV-2 감염의 치료를 위한 25-히드록시비타민 D | |
| Spies et al. | Prednisone chronotherapy | |
| Deodhar et al. | POS0939 Bimekizumab in patients with active non-radiographic axial spondyloarthritis: 24-week efficacy & safety from be mobile 1, a phase 3, multicentre, randomised, placebo‑controlled study | |
| Sands et al. | New life in a sleeper: thalidomide and Crohn's disease |